Artelo Biosciences jumps as it plans UK study of glaucoma drug
18/03/2026 11:49
** Shares of biotech firm Artelo Biosciences ARTL.O rise 55% to $7.35 premarket ** Co says it will test experimental cannabinoid drug, ART27.13, in glaucoma, an eye disease that damages vision by raising pressure inside the eye ** Says study in the UK will see if the oral capsule can safely lower eye pressure in people with glaucoma or ocular hypertension, a condition with higher‑than‑normal eye pressure ** Trial funded by Glaucoma UK and HSC R&D; patient enrolment to start in Q2 2026, co says ** Drug is designed to work outside the brain to avoid “high” or mind‑altering effects, co says ** ART27.13 is also being tested for cancer‑related weight loss; co says glaucoma study could expand its use - ARTL ** Shares down ~81% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))